Emcure Q1FY27: consolidated PAT up 36% YoY to ₹292 Cr, margins expand, revenue +23%

Emcure's consolidated revenue rose 22.8% YoY to ₹2,580.4 Cr in Q1 FY27 (+4.5% QoQ from ₹2,469.7 Cr), while PAT grew faster, up 36.2% YoY to ₹292.5 Cr — the company's own adjusted-PAT measure, which strips out forex and one-offs, grew a still-strong 33.8% YoY to ₹290.9 Cr, confirming the growth isn't primarily one-off driven. QoQ, PAT rose 20.0% off a ₹243.7 Cr base. PAT margin expanded to 11.3%, up 110 bps YoY and 140 bps QoQ. No exceptional items hit the P&L this quarter, unlike Q1 FY26 which absorbed a ₹3.5 Cr one-time legal-settlement cost, so the YoY comparison is close to clean.

International revenue did the heavy lifting, up 34.2% YoY to ₹1,485.1 Cr (57.6% of the mix): Europe grew 32.8% to ₹536.7 Cr on a stronger Liposomal Amphotericin B contribution, Canada grew 24.6% to ₹426.6 Cr, and Rest of World grew 44.8% to ₹521.8 Cr on ARV strength. Domestic grew a slower 10.2% to ₹1,095.3 Cr, helped by CNS, cardiology and women's-health brands plus an execution turnaround at Zuventus. Gross margin compressed 340 bps YoY to 58.4% as the lower-margin international mix grew, but EBITDA margin still expanded 50 bps YoY to 19.7% (EBITDA ₹508.0 Cr, +25.8% YoY) on employee-cost leverage (+4.1% YoY, well below revenue growth), even as freight-cost volatility pushed other expenses up 17.7% YoY.

The stock went into the print at ₹1,939.7, up 7.2% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

Management's FY27 guidance (from the Q4 FY26 call) called for low-to-mid-teen revenue growth and 75-100 bps of full-year EBITDA margin expansion; Q1's 22.8% revenue growth runs well ahead of that band, a beat, while the 50 bps of margin gain trails the low end of the guided full-year pace — a gap pre-result commentary (CompoundingAI's Q1 FY27 preview, no numeric consensus available) had flagged as a freight/solvent-cost risk, and it partly materialized, though margin still expanded rather than compressed. On the standalone entity, PAT was ₹200.1 Cr against the group's ₹292.5 Cr, meaning subsidiaries (Zuventus, Tillomed, Gennova and the LatAm/Africa units) contributed roughly ₹92 Cr of the quarter's profit. The quarter also carried three corporate actions outside the P&L: Emcure completed the buyout of the 12.05% minority stake in Gennova Biopharmaceuticals, making it a wholly owned subsidiary effective July 21; Gennova concurrently divested its mRNA business for ₹139.5 Cr; and the Sanand manufacturing facility was placed under US FDA Import Alert 66-40 on July 21 — a risk not addressed in management's press release, though external preview commentary pegs direct US exposure at under 3% of revenue.